Tetrapeptide inhibitors of β-secretase

Details Tetrapeptide inhibitors of β-secretase Tetrapeptide inhibitors of β-secretase

2007-01-30

2007-01-30

Campell, Bruce R. (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S387900, C530S388100, C530S388260, C530S389100, C530S389200

Reexamination Certificate

active

09594667

ABSTRACT:
Statine-derived peptide inhibitors of the β-secretase enzyme are provided which are useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of Aβ peptide in a mammal. The compounds of the invention provide useful methods of treatment by administration of these inhibitors to reduce Aβ peptide formation and pharmaceutical compositions.

REFERENCES:
patent: 4397786 (1983-08-01), Evans et al.
patent: 4522811 (1985-06-01), Eppstien et al.
patent: 4636491 (1987-01-01), Bock et al.
patent: 6627739 (2003-09-01), Anderson
Bock, Mark G., et al. “Renin Inhibitors Containing Hydrophilic Groups. Tetrapeptides with Enhanced Aqueous Solubility and Nanomolar Potency”J. Med. Chem.., 31:1918-1923, 1988.
Agarwal, Nirankar S., et al. “Inhibition of Cathepsin D by Substrate Analogues Containing Statine and by Analogues of Pepstatin”J. Med. Chem., 29:2519-2524.
Bringmann, G., et al. “Enantiomerically Pure N-Boc Protected β-Keto-γ-Amino Acid Esters form Simple Keto PrecursorsL A Novel, Sterocontrolled Approach to Statine Derivatives with Any Desired Configuration”Synlett, 5:253-255, 1990.
Cintas, P., “Asymmetric synthesis of α-amino acids from carbohydrates as chiral templates.”Tetrahedron, 47(32):6079-6111, 1991.
Fieser, Mary, et al.,Reagents for Org. Syn., 4:418, 1974.
Freifelder, Morris, et al., “Low-pressure Hydrogenation of Alkozyanilines with Nobel Metal Catalysts”J. Org. Chem., 30:2485-6, 1965.
Kessler, Horst, et al., “Short and Efficient Synthesis of Statine and Isostatine Derivatives”Synthesis, 6:457-458, 1990.
Korotzer, Andrew, et al. “Differential regulation by beta-amyloid peptides of intracellular free Ca2+ concentration in cultured rat microglia.”Eur. J. Pharmacol, 288(2):125-130, 1995.
Kowall, Neil, et al. “Anin vivomodel for the neurodegenerative effects of β amyloid and protection by substance”Proc Natl Acad Sci USA, 88(16):7247-7251, 1991.
Lehninger, A.L.,Biochemistry: The Molecular Basis of Cell Structure and Function, Chapter 4, Worth Publishers, NY, pp. 71-94, 1975.
Nishi, Takahide, et al., “The Practical Synthesis ofN-Protected Allylamine: The Isoxazoline Route to Statine Analogue”Heterocycles, 29(9):1835-1842, 1989.
Precigoux, G. et al. “X-ray crystallography of linear peptides through renin-angiotesin system.”Peptides Biol. Fluids, 35:476-476 (abstract), 1987.
Rich, Daniel, “Pepstatine-Derived Inhibitors of Aspartic Proteinases. A Close Look at an Apparent Transition-State Analogue Inhibitor”J. Med. Chem., 28(3):263-273, 1985.
Sabbagh, M., et al. “β-Amyloid and Treatment Opportunities for Alzheimer's Disease.”Alz. Dis. Rev., 3:1-19, 1997.
Seubert, et al., “Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids”Nature, 359:325-327, 1992.
Shiosaki, K. et al. “Potent and selective inhibitors of an aspartyl protease-like endothelin converting enzyme identified in rat lung.”J. Med. Chem., 36(4):468-478, 1993.
Paruszewski, R., et al., Enzymatically stable renin inhibitors containing statin and 6 aminohexanoic acid. Part IVBoll. Chim. Farmaceutico, 133(5):301-308, 1994.

Affiliated with

Also associated with

Rating

Tetrapeptide inhibitors of β-secretase does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Tetrapeptide inhibitors of β-secretase, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tetrapeptide inhibitors of β-secretase will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3779079